New drug cocktail aims to stall aggressive head and neck cancers
NCT ID NCT00494182
Summary
This study is testing whether adding the drug sorafenib to two standard chemotherapy drugs (carboplatin and paclitaxel) can better control advanced head and neck cancer that has spread or returned. It aims to see if this combination can slow cancer growth and extend the time patients live without their disease getting worse. The trial is for adults with specific types of head and neck cancer who meet strict health requirements.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
Conditions
Explore the condition pages connected to this study.